Carbonin P U, Greco A, Pisanti P, Gemma A, Cattelin F
Istituto di Clinica Medica, Policlinico Gemelli, Rome, Italy.
Clin Neuropharmacol. 1990;13 Suppl 3:S92-9. doi: 10.1097/00002826-199013003-00010.
Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001).
对与年龄相关的认知障碍进行早期治疗，对于老年患者能否居家养老可能具有决定性意义。对40名患有中度认知障碍的老年门诊患者（25名女性，15名男性；平均年龄：73.5岁）进行了一项关于阿米三嗪萝巴新的双盲、安慰剂对照试验，这些患者被随机分为两组，一组服用阿米三嗪和萝巴新，另一组服用安慰剂，每日两片，持续90天。在第0天、第45天和第90天使用图卢兹 - 皮埃隆测试、韦氏成人智力量表（WAIS）的8个分测验以及老年医学桑多兹临床评估量表（SCAG）对他们进行评估。在所有测试中，阿米三嗪萝巴新组的研究结束时结果均显著更好：图卢兹 - 皮埃隆测试（p小于0.001）、WAIS（p小于0.001）和SCAG（p小于0.001）。
